A5041089236- Acute Ischemic Stroke Management
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Cerebrovascular and Carotid Artery Diseases
- Gastrointestinal motility and disorders
- Traumatic Brain Injury and Neurovascular Disturbances
- Stroke Rehabilitation and Recovery
- Advanced Neuroimaging Techniques and Applications
- Alzheimer's disease research and treatments
- Pancreatic and Hepatic Oncology Research
- Autoimmune and Inflammatory Disorders
- Protease and Inhibitor Mechanisms
- Intracerebral and Subarachnoid Hemorrhage Research
- Dementia and Cognitive Impairment Research
- Medical Device Sterilization and Disinfection
- Chemokine receptors and signaling
- Inflammatory Bowel Disease
- MRI in cancer diagnosis
- Microscopic Colitis
- Advanced MRI Techniques and Applications
- Cell Adhesion Molecules Research
University of Alberta
2023-2025
University of Basel
2023
University of Calgary
2016-2023
NoNO (Canada)
2023
Erlanger Health System
2023
Ottawa Hospital
2023
University of Ottawa
2023
Sunnybrook Health Science Centre
2023
Health Sciences Centre
2023
University of Toronto
2023
Fecal microbiota transplantation (FMT) is the most effective therapy for preventing recurrent Clostridioides difficile infection (rCDI). However, impact of FMT formulations and storage conditions on bacterial viability, community structure, functionality, clinical efficacy remains under-investigated. We studied effect different viability (live/dead staining cell sorting), structure (16S rDNA analysis), metabolic functionality (fermentation) frozen lyophilized formulations. Clinical success...
Fecal microbiota transplantation (FMT) is the most effective therapy for preventing recurrent Clostridioides difficile infection (rCDI). However, impact of FMT formulations and storage conditions on bacterial viability, community structure, functionality, clinical efficacy remains under-investigated. We studied effect different viability (live/dead staining cell sorting), structure (16S rDNA analysis), metabolic functionality (fermentation) frozen lyophilized formulations. The success rates...
The neuroprotectant nerinetide has shown promise in reducing infarct volumes primate models of ischemia reperfusion. We hypothesized that early secondary growth after endovascular therapy (EVT) (1) may be a suitable surrogate biomarker for testing neuroprotective compounds, (2) is feasible to assess the acute setting using sequential MRI, and (3) can modified by treatment with nerinetide.
<h3>BACKGROUND AND PURPOSE:</h3> Infarct core volume measurement using CTP (CT perfusion) is a mainstay paradigm for stroke treatment decision-making. Yet, there are several downfalls with cine technology that can be overcome by adopting the simple perfusion reconstruction algorithm (SPIRAL) derived from multiphase CTA. We compare SPIRAL parameters prediction of 24-hour infarction. <h3>MATERIALS METHODS:</h3> Seventy-two patients had admission NCCT, CTA, CTP, and DWI. All successful/quality...
Monocyte chemoattractant protein-1 (MCP-1) has been reported to induce the expression of monocyte chemotactic protein-induced protein 1 (MCPIP1), which undergoes ubiquitination degradation. Therefore, we predict that in vascular smooth muscle (VSMCs), MCPIP1 may be induced by MCP-1 and undergo degradation, can inhibited proteasome inhibitor, MG132. Our results showed treatment human VSMCs with did not increase MCPIP1. Treatment MG132, however, elevated levels through stimulation gene...
Rationale Following endovascular treatment, poor clinical outcomes are more frequent if the initial infarct core or volume of irreversible brain damage is large. Clinical may be improved using neuroprotective agents that reduce stroke and improve recovery. Aim The aim REPERFUSE NA1 was to replicate preclinical neuroprotection study significantly reduced in a primate model ischemia reperfusion. Specifically, will determine administration neuroprotectant prior therapy can early (Day 2 subtract...
Structural brain changes indicative of dementia occur up to 20 years before the onset clinical symptoms. Efforts modify disease process after cognitive symptoms have been unsuccessful in recent years. Thus, future trials must begin during preclinical phases symptom onset. Age related decline is often result two coexisting pathologies: Alzheimer's (amyloid, tau, and neurodegeneration) vascular disease. This review article highlights some common neuroimaging techniques used visualize...
Background: Early infarct growth after endovascular therapy (EVT) may lead to unfavorable outcomes despite successful reperfusion. The REPERFUSE-NA1 study replicated the preclinical NA1 experiment by investigating effect of on early DWI in acute ischemic stroke patients receiving EVT. Methods: was a sub-study randomized controlled trial ESCAPE-NA1 (ClinicalTrialGov NCT02930018). Patients received MRI within 5 hours and 24 primary outcome diffusion weighted (DWI) growth. secondary...